Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | FAAH | O00519 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.62 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.60 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.57 |
| ▸ | CPT2 | P23786 | 1/20 | 0.55 |
| ▸ | CPT1A | P50416 | 1/20 | 0.55 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 3/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14159281 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL3243330 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL23799220 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL26393720 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL29893217 | 0.98 | DNM1 (0.65) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL13225189 | 0.92 | DNM1 (0.64) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL7622211 | 0.92 | DNM1 (0.64) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL7624358 | 0.92 | DNM1 (0.64) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL7622216 | 0.92 | DNM1 (0.64) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL3100590 | 0.92 | DNM1 (0.64) | DNM1MEN1KMT2AFAAHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024261-A1 | PHARMACEUTICAL COMPOSITION FOR IMPROVING COGNITIVE ABILITY OR ENHANCING MEMORY | DR. RAYMOND LAB INC (KR) | 2024-01-25 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-111295181-B | Composition for external application to skin | 雷蒙德博士实验室 | 2022-10-25 | — | — | CN | claimed |
| WO-2022058940-A1 | PHARMACEUTICAL COMPOSITION FOR IMPROVING COGNITIVE ABILITY OR ENHANCING MEMORY | 닥터레이몬드 랩(주) | 2022-03-24 | — | — | WO | claimed |
| US-20220050090-A1 | MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF MICROBIOTA RELATED METABOLITES | METABOLON, INC. | 2022-02-17 | — | — | US | claimed |
| US-10987293-B2 | Composition for skin external application | DR. RAYMOND LABORATORIES, INC. (US) | 2021-04-27 | — | — | US | claimed |
| US-20200276096-A1 | COMPOSITION FOR SKIN EXTERNAL APPLICATION | DR. RAYMOND LABORATORIES, INC. | 2020-09-03 | — | — | US | claimed |
| EP-3677247-A1 | COMPOSITION FOR SKIN EXTERNAL APPLICATION | Dr. Raymond Laboratories, Inc. (US) | 2020-07-08 | — | — | EP | claimed |
| WO-2019172572-A1 | COMPOSITION FOR SKIN EXTERNAL APPLICATION | 닥터 레이몬드 래보라토리 | 2019-09-12 | — | — | WO | claimed |
| WO-2009100116-A1 | OLIGODENDROCYTE PRECURSOR CELL COMPOSITION AND METHODS OF USE | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | claimed |
| US-20090196859-A1 | Oligodendrocyte Precursor Cell Composition and Methods of Use | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-08-06 | — | — | US | claimed |
| US-7445931-B2 | Culturing differentiating pluripotent human cell with N-palmitoyl serinol or N-oleoyl serinol in serum-free medium; modulating apoptosis | BRESAGEN, INC. (US) | 2008-11-04 | — | — | US | claimed |
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | EPITECH GROUP S.R.L. (IT) | 2007-11-22 | — | — | US | claimed |
| EP-1844784-A1 | A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | Epitech Group S.r.l. (IT) | 2007-10-17 | — | — | EP | claimed |
| EP-4745844-A1 | FRAMEWORK FOR SIMULATION AND CROSS-PLATFORM DEPLOYMENT OF SPIKING NEURAL NETWORK MODELS | Tata Consultancy Services Limited (IN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260134295-A1 | FRAMEWORK FOR SIMULATION AND CROSS-PLATFORM DEPLOYMENT OF SPIKING NEURAL NETWORK MODELS | TATA CONSULTANCY SERVICES LIMITED (IN) | 2026-05-14 | — | — | US | disclosed |
| US-20260053778-A1 | USE OF NOVEL PPAR ACTIVITY MODULATOR FOR PREVENTION, AMELIORATION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES | POSTECH Research and Business Development Foundation (KR) | 2026-02-26 | — | — | US | disclosed |
| US-5990170-A | POSSESSES A PROFILE OF ACTIVITY WHICH IS SIMILAR TO, THOUGH LESS POTENT THAN .DELTA.9-THC (TETRAHYDROCANNABINOL) WITH A MIMICKING OF THE PSYCHOACTIVE EFFECTS; ANALGESICS; SIDE EFFECT REDUCTION; CARDIOVASCULAR DISORDERS | LIFEGROUP S.P.A. (IT) | 1999-11-23 | — | — | US | disclosed |
| EP-0799033-A1 | USE OF MONO AND BICARBOXYLIC ACID AMIDES FOR THE MANUFACTURE OF A MEDICAMENT ACTIVE AT THE PERIPHERAL CANNABINOID RECEPTOR | LIFEGROUP S.p.A. (IT) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996018391-A2 | USE OF MONO AND BICARBOXYLIC ACID AMIDES FOR THE MANUFACTURE OF A MEDICAMENT ACTIVE AT THE PERIPHERAL CANNABINOID RECEPTOR | LIFEGROUP S.P.A. (IT) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260134295-A1 | FRAMEWORK FOR SIMULATION AND CROSS-PLATFORM DEPLOYMENT OF SPIKING NEURAL NETWORK MODELS | NCS1, HCN2, HCN1 | DNM1 488/4885MEN1 1137/4885KMT2A 3031/4885 |
| US-10987293-B2 | Composition for skin external application | CNR1, CUTA, CNR2 | DNM1 419/4885MEN1 4463/4885KMT2A 1930/4885 |
| US-20260053778-A1 | USE OF NOVEL PPAR ACTIVITY MODULATOR FOR PREVENTION, AMELIORATION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES | PPARA, PPARD, PPARG | DNM1 1161/4885MEN1 4855/4885KMT2A 3309/4885 |
| US-20200276096-A1 | COMPOSITION FOR SKIN EXTERNAL APPLICATION | CNR1, CUTA, CNR2 | DNM1 419/4885MEN1 4463/4885KMT2A 1930/4885 |
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | HCAR2, HCAR1, MYD88 | DNM1 2997/4885MEN1 1658/4885KMT2A 3832/4885 |
| US-20090196859-A1 | Oligodendrocyte Precursor Cell Composition and Methods of Use | SGMS1, S1PR1, S1PR3 | DNM1 202/4885MEN1 1563/4885KMT2A 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.